Advertisement

Topics

Deals this week: Biohaven Therapeutics, POXEL, Ossianix

19:00 EDT 6 Sep 2018 | Net Resources International

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....
Read More...

The post Deals this week: Biohaven Therapeutics, POXEL, Ossianix appeared first on Drug Development Technology.

Original Article: Deals this week: Biohaven Therapeutics, POXEL, Ossianix

NEXT ARTICLE

More From BioPortfolio on "Deals this week: Biohaven Therapeutics, POXEL, Ossianix"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...